Please login to the form below

Not currently logged in


This page shows the latest IOmet news and features for those working in and with pharma, biotech and healthcare.

Merck & Co buys another immuno-oncology target

Merck & Co buys another immuno-oncology target

Other deals have included the acquisitions of IOmet last year, cCAM Biotherapeutics in 2015 and OncoEthix a year earlier.

Latest news

  • Merck & Co buys IOmet to boost immuno-oncology tech Merck & Co buys IOmet to boost immuno-oncology tech

    IOmet will become a wholly owned subsidiary of Merck after the transaction goes through, according to Merck. ... IOmet's chief executive Alan Wise said becoming part of Merck "creates significant opportunity for us to advance the treatment of cancer.".

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...